March 8, 2021

glimworm

Advances in world technology

Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Engineering for HIV Remedy

FOSTER Town, Calif. & EMERYVILLE, Calif.–(Company WIRE)–Feb 1, 2021– Gilead Sciences, Inc. (Nasdaq: GILD) and...

FOSTER Town, Calif. & EMERYVILLE, Calif.–(Company WIRE)–Feb 1, 2021–

Gilead Sciences, Inc. (Nasdaq: GILD) and Gritstone Oncology, Inc. (Nasdaq: GRTS), a medical-stage biotechnology organization developing future technology cancer and infectious disease immunotherapies, today introduced that the firms have entered into a collaboration, selection and license arrangement to research and acquire a vaccine-primarily based immunotherapy as component of Gilead’s efforts to come across a curative therapy for human immunodeficiency virus (HIV) an infection.

This press release functions multimedia. Look at the full launch here: https://www.businesswire.com/news/dwelling/20210201005208/en/

Gilead and Gritstone will establish an HIV-distinct therapeutic vaccine utilizing Gritstone’s proprietary key-boost vaccine system, comprised of self-amplifying mRNA (SAM) and adenoviral vectors, with antigens made by Gilead.

“While HIV remedy has innovative dramatically more than the previous three a long time, people living with HIV even now deal with a life time of remedy,” said Diana Brainard, MD, Senior Vice President, Virology Therapeutic Place, Gilead Sciences. “Curing HIV stays the top aspiration for Gilead’s HIV investigate and growth endeavours. Gritstone’s vaccine know-how has the potential to teach the immune technique to specifically figure out and wipe out HIV-contaminated cells by leveraging SAM and adenoviral vectors. This, alongside with our other partnerships and internal systems, displays Gilead’s commitment to continuing innovation to find a cure for HIV and carry about an conclusion to the HIV epidemic.”

“We are psyched to be partnering with Gilead, a corporation that has many years lengthy practical experience increasing treatment for men and women residing with HIV, to progress a novel immunotherapy making use of our proprietary system for the remedy of HIV infection,” explained Andrew Allen, MD, PhD, Co-Founder, President and Chief Government Officer of Gritstone. “It is properly-recognized that CD8+ T cells are critical for the elimination of virally infected cells, and we have developed a very differentiated vaccine platform that has been demonstrated to create significant figures of antigen-certain T cells, which includes CD8+ T cells, even in sophisticated and immunocompromised cancer sufferers. On the heels of our current COVID-19 method initiation in partnership with the NIH, this software provides to our rising infectious disease pipeline supported by collaborations with primary biopharma and renowned institutions.”

“Delivery of viral antigens in powerful vaccine vectors to elicit a strong immune reaction is a cornerstone of profitable infectious condition vaccines,” stated Karin Jooss, PhD, Executive Vice President of Research and Chief Scientific Officer of Gritstone. “Our preclinical operate at Gritstone establishing our powerful prime-strengthen vaccine technology utilized simian immunodeficiency virus (SIV) derived antigens as model antigens, which are extremely related to HIV-1. The resulting sturdy, resilient and broad anti-SIV CD8+ T cell responses and T cell memory details captured the interest of Gilead’s virology workforce. We jointly executed further more experiments that created further persuasive details, which was also complemented by our interesting medical details with neoantigens in cancer patients. We are delighted to now advance our partnership and merchandise candidates for the cure of sufferers with HIV an infection.”

Conditions of the Agreement

Underneath the terms of the arrangement, Gilead will make a $60 million payment at closing, consisting of a $30 million upfront funds payment and a $30 million equity investment decision at a quality. Gilead will be liable for conducting a Section 1 research for the HIV-certain therapeutic vaccine and holds an distinctive choice under the collaboration to acquire an special license to establish and commercialize the HIV-particular therapeutic vaccine further than Stage 1. Gritstone is also suitable to get up to an extra $725 million if the selection is exercised and if particular clinical, regulatory and professional milestones are obtained, as nicely as mid single-digit to very low double-digit tiered royalties on net income on commercialization.

Locust Stroll served as transaction advisor to Gritstone.

About Gritstone Oncology

Gritstone Oncology (Nasdaq: GRTS), a medical-stage biotechnology firm, is building the up coming era of immunotherapies towards several most cancers varieties and infectious ailments. Gritstone develops its products by leveraging two crucial pillars—first, a proprietary device finding out-primarily based platform, Gritstone EDGE™, which is designed to forecast antigens that are introduced on the surface area of cells, this sort of as tumor or virally-infected cells, that can be witnessed by the immune program and 2nd, the skill to build and manufacture powerful immunotherapies making use of these antigens to likely travel the patient’s immune system to particularly assault and demolish condition-resulting in cells. The company’s lead oncology courses include an individualized neoantigen-based immunotherapy, GRANITE, and an “off the shelf” shared neoantigen-dependent immunotherapy, SLATE, which are staying evaluated in clinical scientific tests. The company also has a bispecific antibody (BiSAb) software for reliable tumors in direct optimization. Within just its infectious ailment pipeline, Gritstone is advancing CORAL, a COVID-19 system to develop a second-era vaccine with assist from departments in the Countrywide Institutes of Health (NIH) and the Invoice & Melinda Gates Basis and a license arrangement with La Jolla Institute for Immunology. Moreover, the company has a world wide collaboration for the progress of a therapeutic HIV vaccine with Gilead Sciences. For much more information and facts, please pay a visit to gritstoneoncology.com.

About Gilead Sciences

Gilead Sciences, Inc. is a investigation-centered biopharmaceutical firm that discovers, develops and commercializes progressive medicines in locations of unmet health care will need. The organization strives to transform and simplify treatment for men and women with life-threatening diseases all around the globe. Gilead has operations in additional than 35 international locations worldwide, with headquarters in Foster City, California. For extra info on Gilead Sciences, remember to check out the company’s web page at www.gilead.com.

Gritstone Ahead-Wanting Statements

This push release incorporates ahead-seeking statements, like, but not limited to, statements relevant to the opportunity of Gritstone’s therapeutic systems the improvements in the Company’s ongoing medical trials the timing of information bulletins related to ongoing scientific trials and the initiation of long term clinical trials.

This kind of forward-seeking statements involve substantial challenges and uncertainties that could lead to Gritstone’s analysis and scientific progress packages, potential final results, performance or achievements to vary significantly from all those expressed or implied by the ahead-searching statements. This kind of dangers and uncertainties contain, amongst others, the uncertainties inherent in the drug growth method, which includes Gritstone’s programs’ early stage of advancement, the course of action of building and conducting preclinical and medical trials, the regulatory approval processes, the timing of regulatory filings, the challenges related with production drug products, Gritstone’s means to productively build, guard and defend its mental house and other matters that could have an affect on the sufficiency of existing cash to fund functions. Gritstone undertakes no obligation to update or revise any forward-looking statements. For a even more description of the hazards and uncertainties that could trigger real success to vary from individuals expressed in these forward-wanting statements, as well as risks relating to the small business of the business in common, see Gritstone’s most recent Quarterly Report on Variety 10-Q submitted on November 5, 2020 and any existing and periodic reports filed with the Securities and Trade Fee.

Gilead Forward-Hunting Statements

This push launch features forward-looking statements in just the this means of the Private Securities Litigation Reform Act of 1995 that are issue to risks, uncertainties and other components, such as the skill of the parties to satisfy likely milestones in the approximated timelines or at all and the hazard that the events could not recognize the expected benefits of this collaboration. All statements other than statements of historical actuality are statements that could be deemed ahead-on the lookout statements. These threats, uncertainties and other variables could trigger genuine final results to vary materially from those referred to in the ahead-looking statements. The reader is cautioned not to count on these forward-seeking statements. These and other challenges are described in depth in Gilead’s Quarterly Report on Kind 10-Q for the quarter ended September 30, 2020, as filed with the U.S. Securities and Trade Commission. All forward-wanting statements are primarily based on information and facts at the moment available to Gilead, and Gilead assumes no obligation to update any this kind of ahead-wanting statements.

Check out supply variation on businesswire.com:https://www.businesswire.com/news/house/20210201005208/en/

Get in touch with: Gilead Contacts:

Jacquie Ross, Investors

(650) 425-8408Mark Snyder, Media

(650) 446-6957Gritstone Contacts:

Alexandra Santos, Investors

(510) 871-6161Dan Budwick, Media

(973) 271-6085

Key phrase: CALIFORNIA UNITED STATES NORTH The us

Market Key phrase: ONCOLOGY AIDS Wellbeing INFECTIOUS Disorders HOSPITALS PHARMACEUTICAL BIOTECHNOLOGY

Resource: Gilead Sciences, Inc.

Copyright Business Wire 2021.

PUB: 02/01/2021 06:00 AM/DISC: 02/01/2021 06:01 AM

http://www.businesswire.com/news/dwelling/20210201005208/en